Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 734 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetic Vascular Diseases Clear all
Completed No phase listed Observational

Vascular Reactivity in Metabolic Syndrome and Diabetic Patients Using Diffuse Optical Spectroscopy

NCT00793481
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Diffuse Optical Spectroscopy
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
45 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 4, 2026, 10:10 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

NCT04419467
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
CSL346, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
25 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Covina, California • Fresno, California • Lomita, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 4, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

NCT05063734
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 4, 2026, 10:10 PM EDT
Recruiting Phase 4 Interventional

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

NCT07172893
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Interventions
DermaBind TL
Biological
Lead sponsor
HealthTech Wound Care
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
DeLand, Florida • Palm Beach Gardens, Florida • Sweetwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Walking and Heating on Vascular Function in Diabetic Patients

NCT03203694
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Walking: Intervention arm in diabetics, Walking: No intervention in diabetics, Walking: Healthy cohort as reference controls, Lower body heating: Intervention arm in healthy subjects, Lower body heating: Intervention arm in diabetics, Lower body heating: Healthy cohort as reference controls
Behavioral · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Patient Navigator Intervention for Diabetic Retinopathy

NCT05188703
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Blindness
Interventions
Patient Navigation
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 4, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional

Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers

NCT07161830
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Omeza® Complete Matrix, Standard of Care
Device · Other
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Evergreen Park, Illinois • Denham Springs, Louisiana • Leesville, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 4, 2026, 10:10 PM EDT
Not listed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers

NCT04497805
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-SHEET
Biological
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 4, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Risk Progression in Normal and Diabetic Control Subjects.

NCT00579228
View directory record Official record
Conditions
Diabetes, Inflammation
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828
View directory record Official record
Conditions
Iris Neovascularization, Diabetic Retinopathy
Interventions
Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
Other · Procedure
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Oct 4, 2026, 10:10 PM EDT
Not listed Phase 4 Interventional

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

NCT01095822
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Aliskiren + Valsartan
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Phase 4 Interventional

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

NCT04708145
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Aflibercept Injection
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Beverly Hills, California • Orlando, Florida • Winter Haven, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 4, 2026, 10:10 PM EDT
Completed No phase listed Observational

ARDA Software for the Detection of mtmDR

NCT04905459
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ARDA software application
Diagnostic Test
Lead sponsor
Verily Life Sciences LLC
Industry
Eligibility
22 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Glendale, Arizona • Jonesboro, Arkansas • Montclair, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 4, 2026, 10:10 PM EDT
Enrolling by invitation No phase listed Observational

Clinical Registry Collecting Real World Evidence on Wound Care Treatments

NCT06328010
View directory record Official record
Conditions
Wounds and Injuries, Burns, Mohs Surgery, Diabetic Foot Ulcer Mixed, Venous Leg Ulcer, Non-healing Wound, Trauma Injury, Injury and Wounds, Degloving Injuries, Pressure Ulcers, Bedsores, Decubitus Ulcer
Interventions
Various types of wound care treatments
Combination Product
Lead sponsor
Siddhey LLC
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
12
States / cities
Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Collaborative Care for Depression and Diabetic Retinopathy in African Americans

NCT02121340
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Behavioral Activation
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 4, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional

Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation

NCT07223268
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
CARE-D-Foot-Nav, Standard of care
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

NCT00446459
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 4, 2026, 10:10 PM EDT
Completed No phase listed Observational

Spatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and Healing

NCT03341559
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Spatial Frequency Domain Imaging (SFDI)
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 4, 2026, 10:10 PM EDT
Not listed Not applicable Interventional

A Feasibility Study of Advance Plasma Therapy001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers

NCT03078933
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, Nitric Oxide Therapy 2x week 6 min. plus standard of care, Nitric Oxide Therapy 2x week 12 min. plus standard of care, Nitric Oxide Therapy 4x week 6 min. plus standard of care, Nitric Oxide Therapy 4x week 12 min. plus standard of care
Device
Lead sponsor
Origin Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 4, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

NCT00782340
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
Interventions
Placebo, Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 4, 2026, 10:10 PM EDT
Recruiting No phase listed Observational

A Real-World Registry of Chronic Wounds and Ulcers

NCT02280733
View directory record Official record
Conditions
Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis, Skin Ulcer, Leg Ulcer, Pyoderma, Peripheral Arterial Disease, Lymphedema, Surgical Complication, Venous Leg Ulcers (VLUs), Calciphylaxis, Sickle Cell Ulcer, Pressure Ulcer (PU), Diabetic Foot Ulcers (DFUs), Pressure Injury, Arterial Ulcers, Soft Tissue Radionecrosis (STRN), Traumatic Wounds, Chronic Ulcer
Interventions
Usual care
Other
Lead sponsor
U.S. Wound Registry
Other
Eligibility
Not listed
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 4, 2026, 10:10 PM EDT